title: [HIV 2012 : research update].
abstract: HIV therapy is able to achieve complete viral suppression in up to 90% of patients. Thus, most patients will benefit from long-term effective and tolerable therapy combinations. Antiretroviral therapy, however, can still lead to side effects, is costly, and its success is dependent on sufficient health system resources and access to different drug combinations. Established tools in prevention and novel approaches to avoid spread of HIV infection are crucial to combat the epidemic. Recent advances in research about how drug regimens stop viral transmission ("treatment as prevention"), how the immune system defends against HIV (natural killer cells, broad neutralizing antibodies), and how cellular factors restrict viral replication are import milestones on the long way to stopping the global epidemic and to fostering vaccine development.
authors.affiliation: Klinik für Immunologie und Rheumatologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland. behrens.georg@mh-hannover.de
authors.forename: G M N
authors.initials: GM
authors.lastname: Behrens
mesh_terms: D016915:AIDS Vaccines / Q000627:therapeutic use*; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D035843:Biomedical Research / Q000639:trends*; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans
chemical_list: D016915:AIDS Vaccines; D044966:Anti-Retroviral Agents